Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
* Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso * PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies * Full Data Set to be P...
Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced thatthe positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb)combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or ...
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC
HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...
The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research
HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had be...
Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced thatMichelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new bispecific a...
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab(开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XEL...
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy
HONG KONG, Nov. 28, 2023 /PRNewswire/ -- The groundbreaking ceremony for Akeso (9926.HK) Shanghai Global R&D Center was successfully held at the Zhangjiang headquarters park inShanghai. The establishment of the Akeso Global R&D Center signifies a crucial step in Akeso's innovative globalization ...
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients
HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-fre...
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...
Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...
Journal of Thoracic Oncology Published Promising Results of Ivonescimab (PD-1/VEGF Bispecific) as First- or Second-line Therapy for Advanced or Metastatic Immunotherapy Naïve Non-Small-Cell Lung Cancer
HONG KONG, Oct. 30, 2023 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase Ib clinical trial for PD-1/VEGF bispecific antibody ( ivonecimab AK112/SMT112 ) as first- or second-line therapy for advanced or metastatic immunotherapy naïve non-small-cell lung cancer (NSCLC) were p...
Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO
HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...
Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy
HONG KONG, Oct. 19, 2023 /PRNewswire/ -- Akeso (9926. HK) announced the publication of the phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced solid tumors in Cell Reports Medicine, a sub-publication of Cell. Full ar...
Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)
HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced s...
Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso's globally first PD-1/CTLA-4 bispecific antibody, cadonilimab ...
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azaciti...
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit ofRMB2,489.5 million. —RMB2,915.2 million was recognized by Akeso as license fee income during the reporting period due to the receipt of an upfront payment equivalen...
